Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
2022 · BMC Cancer · 20 citations
https://doi.org/10.1186/s12885-022-09364-z
D
Della Varghese
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
570
Citations
7
h-index
5
i10-index
Della Varghese is an academic researcher from AstraZeneca (Switzerland). The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 7, co-authored 23 publications.
Papers by this author
worksTreatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study
2025 · The Oncologist · 4 citations
https://doi.org/10.1093/oncolo/oyae280
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
2024 · International Journal of Clinical Oncology · 2 citations
https://doi.org/10.1007/s10147-024-02492-5
Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer – a cohort study in US electronic health record data
2025 · BMC Cancer · 0 citations
https://doi.org/10.1186/s12885-025-14786-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat